Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

062IC - AUA Guidelines on Non-Muscle Invasive Bladder Cancer

Monday, May 21
7:30 AM - 9:30 AM
Location: MCC WEST, 2004

This course will review the process, data, and rationale for the recommendations outlined in the 2016 Guidelines. The evidence will be reviewed and questions will be answered in regards to clinical situations in which physicians and advanced practice providers may face. Updated literature will also be presented as well as future directions.

Learning Objectives:

Sam S. Chang

Vice-Chair and Patricia and Rodes Hart Professor of Urologic Surgery
Vanderbilt University Medical Center

Sam S. Chang, MD, Patricia and Rodes Hart Endowed Professor of Urologic Surgery and Oncology, is the Oncology Fellowship Director and Vice-Chair of Urologic Surgery at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Chang,a graduate of Princeton University and Vanderbilt University Medical School where he earned a full 4-year Justin Potter Scholarship, completed his uro-oncology fellowship as Chief Fellow at Memorial Sloan-Kettering Cancer Center. He has also recently completed his MBA at Vanderbilt’s Owen School.
Since his return to Nashville, he has focused on urologic oncology and education and has led efforts in integration of evidence-based medicine in clinical pathways, enhanced guidelines formulation, and improved cancer staging. He has orchestrated the initiation and expansion of multiple cancer-related treatment protocols at Vanderbilt and elsewhere. Dr. Chang has served as the Chairman of the SUO Panel on Hormone Refractory Prostate Cancer, the chair of the American Joint Committee on Cancer GU Staging Task Force, the Chair of the AUA Guidelines on Noninvasive Bladder Cancer, the Facilitator of the Renal Malignancy Follow-Up AUA Guidelines Panel, and Chairman of the AUA Prostate Cancer Core Curriculum Committee. He is a current member of the NCCN Kidney Cancer Panel and Chair of the AUA/ASCO/ASTRO/SUO Bladder Cancer Guidelines Panel. In addition, he was an AUA-EAU Academic Exchange Fellow. Dr. Chang has authored more than 250 original publications, multiple book chapters and edited several textbooks. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, a CaPCURE Young Investigator Award, and has been named multiple times as a Journal of Urology’s Best Reviewer. Dr. Chang was named as the 2011 recipient of the American Urologic Association Gold Cystoscope Award and completed a term as a Fellow of the Nashville Health Care Council in 2016.

Presentation(s):

Send Email for Sam Chang

James M. McKiernan

Columbia University

James McKiernan, MD is the John K. Lattimer Professor and Chairman of the Department of Urology of the College of Physicians and Surgeons and urologist-in-chief at New York-Presbyterian/Columbia. The Department of Urology at Columbia is currently ranked 5th in NIH research funding in America and NewYork-Presbyterian’s urology program ranked No. 6 in the latest U.S. News & World Report ranking of America’s best hospitals. Dr. McKiernan graduated from Johns Hopkins University with a BA in biology and received his MD from Columbia University College of Physicians and Surgeons. He completed his training in urology and general surgery at Columbia Presbyterian, followed by a urologic surgical oncology fellowship at Memorial Sloan-Kettering Cancer Center. Dr. McKiernan specializes in urologic oncology, particularly surgical therapy in high-risk patients with bladder and kidney cancers. His research focuses on developing novel therapeutics for bladder cancer treatment as well as comparative effectiveness research in urologic oncology. In addition, Dr. McKiernan is the principal investigator of the NIH-funded clinical trials program of experimental therapeutics in bladder cancer at Columbia, which is investigating new agents for bladder preservation in patients whose cancer has recurred after standard therapy. In collaboration with researchers at Columbia’s Herbert Irving Comprehensive Cancer Center, his team continues to develop novel translational therapeutic strategies for treating bladder cancer.
Dr. McKiernan’s research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 200 scientific articles and book chapters on urologic oncology.
He has served as the Vice Chairman for the AJCC TNM Staging Task Force, Vice-Chair of the AUA Guidelines Panel on non-muscle invasive bladder cancer, as well as on the American Board of Urology and Society of Urologic Oncology Examination Committees.

Presentation(s):

Send Email for James McKiernan

Chad R. Ritch

University of Miami

Dr. Ritch is a fellowship-trained Urologic Oncologist, and currently an Assistant Professor of Urology at the University of Miami, Miller School of Medicine. His clinical interests include the treatment of prostate, bladder, kidney and testicular cancer. His research interests are in prostate and bladder cancer and he serves as PI for a pilot trial investigating the role of nutrition intervention in patients undergoing radical cystectomy. He is a member of the AUA Guideline Panel for the Management of Non-muscle Invasive Bladder Cancer. He did his undergraduate studies at Duke University and then matriculated at the University of Chicago, where he obtained a joint degree in medicine (MD) and business (MBA) from the Pritzker School of Medicine and Booth School of Business. He then completed his residency in Urology at Columbia University Medical Center/NY Presbyterian Hospital followed by a two-year fellowship in Urologic Oncology at Vanderbilt University Medical Center.

Presentation(s):

Send Email for Chad Ritch


Assets

062IC - AUA Guidelines on Non-Muscle Invasive Bladder Cancer



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for AUA Guidelines on Non-Muscle Invasive Bladder Cancer